Julian Francis Burke
Director/Board Member at The Company of Biologists Ltd.
Profile
Julian Francis Burke is currently a Director at The Company of Biologists Ltd.
and a Non-Executive Director at Solentim Ltd.
He previously worked at Genetix Group Ltd.
as an Executive Director & Scientific Director from 1993 to 2010.
Julian Francis Burke active positions
Companies | Position | Start |
---|---|---|
The Company of Biologists Ltd.
The Company of Biologists Ltd. Miscellaneous Commercial ServicesCommercial Services The Company of Biologists Ltd. is a not-for-profit publishing organization that supports and inspires the biological community. The non-profit company is based in Histon, UK. The British company is run by distinguished practicing scientists and exist to profit science, not shareholders. The company publishes leading peer-reviewed journals such as Development, Journal of Cell Science, and Journal of Experimental Biology. The company offers a range of resources to early-career researchers and have chosen the 'transformative' route towards Open Access. The company promotes the use of Caenorhabditis elegans to investigate ten of the 14 cancer hallmarks that define the mechanisms of cancer. | Director/Board Member | - |
Solentim Ltd.
Solentim Ltd. BiotechnologyHealth Technology Part of Advanced Instruments LLC, Solentim Ltd. is a British company that specializes in workflows for antibody and cell-based therapies. The company is based in Wimborne, UK. The company's technologies enable the isolation, growth, and characterization of high-value cells, while their data-driven platform enables smarter decisions earlier in the process. The CEO of the company is Mark Truesdale. Solentim was acquired by Advanced Instruments LLC on September 30, 2021 for $333.83 million. | Director/Board Member | - |
Former positions of Julian Francis Burke
Companies | Position | End |
---|---|---|
Genetix Group Ltd.
Genetix Group Ltd. Medical SpecialtiesHealth Technology Genetix Group Ltd. provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis. The company operates research, pharmaceutical and biotherapeutic developments. Its product brands include ClonePix, Clone Pix FL, Clone Select Imager, Clone Fill, Cell Dispense, QP Expression, QP Display, QP Interactor, OP Evolution, Q Select, O Pix2 XT, O Pix2, MegaPix, QBot, gelPix, gloPix, Q ArrayMini, Q Array2, Q ArrayMax, aliQuot, Q Fill and Mega Pix. Genetix was founded by Mark Reid in 1991 and is headquartered in New Milton, the United Kingdom. | Chief Tech/Sci/R&D Officer | 13/01/2010 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Genetix Group Ltd.
Genetix Group Ltd. Medical SpecialtiesHealth Technology Genetix Group Ltd. provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis. The company operates research, pharmaceutical and biotherapeutic developments. Its product brands include ClonePix, Clone Pix FL, Clone Select Imager, Clone Fill, Cell Dispense, QP Expression, QP Display, QP Interactor, OP Evolution, Q Select, O Pix2 XT, O Pix2, MegaPix, QBot, gelPix, gloPix, Q ArrayMini, Q Array2, Q ArrayMax, aliQuot, Q Fill and Mega Pix. Genetix was founded by Mark Reid in 1991 and is headquartered in New Milton, the United Kingdom. | Health Technology |
The Company of Biologists Ltd.
The Company of Biologists Ltd. Miscellaneous Commercial ServicesCommercial Services The Company of Biologists Ltd. is a not-for-profit publishing organization that supports and inspires the biological community. The non-profit company is based in Histon, UK. The British company is run by distinguished practicing scientists and exist to profit science, not shareholders. The company publishes leading peer-reviewed journals such as Development, Journal of Cell Science, and Journal of Experimental Biology. The company offers a range of resources to early-career researchers and have chosen the 'transformative' route towards Open Access. The company promotes the use of Caenorhabditis elegans to investigate ten of the 14 cancer hallmarks that define the mechanisms of cancer. | Commercial Services |
Solentim Ltd.
Solentim Ltd. BiotechnologyHealth Technology Part of Advanced Instruments LLC, Solentim Ltd. is a British company that specializes in workflows for antibody and cell-based therapies. The company is based in Wimborne, UK. The company's technologies enable the isolation, growth, and characterization of high-value cells, while their data-driven platform enables smarter decisions earlier in the process. The CEO of the company is Mark Truesdale. Solentim was acquired by Advanced Instruments LLC on September 30, 2021 for $333.83 million. | Health Technology |
- Stock Market
- Insiders
- Julian Francis Burke